Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022PRNewsWire • 08/08/22
Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA ReviewPRNewsWire • 06/13/22
Inhibikase Therapeutics, Inc. (IKT) CEO Milton Werner on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period ActivityPRNewsWire • 05/16/22
Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment ConferencePRNewsWire • 05/10/22
Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022PRNewsWire • 05/09/22
Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology ConferencePRNewsWire • 04/21/22
Inhibikase Therapeutics, Inc. (IKT) CEO Dr. Milton Werner on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/01/22
Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period ActivityPRNewsWire • 03/31/22
Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors SummitPRNewsWire • 03/28/22
Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022PRNewsWire • 03/25/22
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth ConferencePRNewsWire • 03/23/22
Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases ConferencePRNewsWire • 03/08/22
Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's DiseasePRNewsWire • 11/29/21
Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period ActivityPRNewsWire • 11/15/21
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009PRNewsWire • 10/19/21
Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's DiseasePRNewsWire • 10/04/21
Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System AtrophyPRNewsWire • 09/23/21
Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/07/21
Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period ActivityPRNewsWire • 08/16/21
Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's PatientsPRNewsWire • 07/26/21